A third, recent study in JAMA Network Open , from August of 2025, analyzed data from 159,000 people with type 2 diabetes who took semaglutide or tirzepatide (Mounjaro, Zepbound)
Shannon Miller, the Kinney Drugs vice president of healthcare operations, said that the program is designed to expand access to weight-loss treatments for Medicare patients who may not have previously had coverage for the medications
In May 2022, tirzepatide (marketed as Mounjaro) received FDA approval for improving blood sugar control in adults with type 2 diabetes, in combination with diet and exercise
The efficacy of DEFA1 is higher than that of the antimicrobial peptide magainin II and the conventional antibiotics ampicillin, clarithromycin or rifampicin, typically used for treatment of Rh
Challenges in the diagnosis of Parkinson's disease
& Su, G